Identification of 9 Genes Differentially Expressed in Head and Neck Squamous Cell Carcinoma
Open Access
- 1 July 2003
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 129 (7) , 754-759
- https://doi.org/10.1001/archotol.129.7.754
Abstract
CURRENT TREATMENT in squamous cell carcinoma (SCC) of the head and neck (HNSCC) is presently based on single or multimodality therapy including surgical resection, radiation, and/or chemotherapy. Unfortunately, these strategies have made little impact on survival in the patient population with HNSCC over the last 20 years.1 Recent investigations have uncovered numerous potential biological targets of therapy for various cancers. From some of these discoveries, novel treatments have been developed, including adenovirus-mediated p53 delivery,2bcr-abl tyrosine kinase inhibition by imatinib mesylate,3 and blockage of human epidermal growth factor receptor (EGFR) and EGFR-2 (HER2) by monoclonal antibodies herceptin and C225, respectively.4,5 Independent of the results of these new therapeutic approaches, efforts must be continued to discover new pathways involved in tumor cell survival, differentiation, invasion, and metastasis.Keywords
This publication has 1 reference indexed in Scilit: